Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

Oral Penicillin Challenge and Allergy De-labeling in Children

Phase 4

Terminated

Conditions: Penicillin Allergy

Interventions: Drug: Amoxicillin 500mg

First Posted Date: 2022-10-03

Last Posted Date: 2024-06-14

Lead Sponsor: Phoenix Children's Hospital

Target Recruit Count: 31

Registration Number: NCT05563610

Locations: 🇺🇸
Phoenix Children's, Phoenix, Arizona, United States

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

Phase 4

Conditions: MPS III B

Interventions: Drug: AX 250

First Posted Date: 2022-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Allievex Corporation

Target Recruit Count: 15

Registration Number: NCT05492799

Locations: 🇩🇪
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
🇬🇧
Great Ormond Street Hospital For Children, NHS Foundation Trust, London, United Kingdom
🇺🇸
UPMC Children's Hospital Pittburgh, Pittsburgh, Pennsylvania, United States

and more 3 locations

Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria

Phase 3

Terminated

Conditions: Severe Acute Malnutrition

Interventions: Drug: Amoxicillin
Drug: Azithromycin

First Posted Date: 2022-07-25

Last Posted Date: 2025-02-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 310

Registration Number: NCT05473234

Locations: 🇳🇬
The Tamaika Project, Gombe, Gombe State, Nigeria

Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Amoxicillin

First Posted Date: 2022-07-22

Last Posted Date: 2024-06-13

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 914

Registration Number: NCT05469685

Locations: 🇨🇳
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
🇨🇳
Changshu No.1 People's Hospital, Suzhou, Jiangsu, China
🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

and more 7 locations

Geisinger Antibiotic Allergy Pilot Program: Assess and Address

Early Phase 1

Recruiting

Conditions: Penicillin Allergy

Interventions: Drug: Amoxicillin

First Posted Date: 2022-07-19

Last Posted Date: 2024-04-30

Lead Sponsor: Geisinger Clinic

Target Recruit Count: 100

Registration Number: NCT05464615

Locations: 🇺🇸
Geisinger Community Medical Center, Scranton, Pennsylvania, United States
🇺🇸
Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States
🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States

Surgical Access Combined With Systematically Administered Antibiotics in the Treatment of Peri-implantitis

Not Applicable

Completed

Conditions: Peri-Implantitis

Interventions: Procedure: Open flap debridement
Drug: Placebos
Drug: Metronidazole
Drug: Amoxicillin

First Posted Date: 2022-07-05

Last Posted Date: 2024-07-18

Lead Sponsor: University of Guarulhos

Target Recruit Count: 89

Registration Number: NCT05444218

Locations: 🇧🇷
University of Guarulhos, Guarulhos, São Paulo, Brazil

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin
Drug: Tetracycline tid
Drug: Tetracycline qid
Drug: Bismuth Potassium Citrate
Drug: Colloidal Bismuth Pectin
Drug: Esomeprazole 20mg

First Posted Date: 2022-06-24

Last Posted Date: 2024-03-27

Lead Sponsor: Shandong University

Target Recruit Count: 406

Registration Number: NCT05431075

Locations: 🇨🇳
Zhengzhou Central Hospital, Zhengzhou, Henan, China
🇨🇳
Qilu hosipital, Jinan, Shandong, China
🇨🇳
Taierzhuang District People's Hospital, Taierzhuang, Shandong, China

and more 3 locations

Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Rabeprazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Colloidal bismuth pectin

First Posted Date: 2022-06-15

Last Posted Date: 2023-02-16

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 393

Registration Number: NCT05419674

Locations: 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Phase 4

Recruiting

Conditions: Endocarditis Infective

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-11

Lead Sponsor: Fundacion Clinic per a la Recerca Biomédica

Target Recruit Count: 360

Registration Number: NCT05398679

Locations: 🇪🇸
Hospital Virgen de la Macarena, Sevilla, Andalucía, Spain
🇪🇸
Hospital Virgen del Rocío, Sevilla, Andalucía, Spain
🇪🇸
Parc Taulí Hospital Universitari, Sabadell, Barcelona, Spain

and more 17 locations

Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection

Phase 4

Recruiting

Conditions: Neutropenic Fever

Interventions: Drug: Meropenem Injection
Drug: Levofloxacin
Drug: Amoxicillin Clavulanate
Drug: Antibiotic

First Posted Date: 2022-05-26

Last Posted Date: 2022-12-06

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 344

Registration Number: NCT05393505

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy